AliCloud, Alibaba Group's cloud computing arm; together with Intel Corporation and BGI, a Beijing-based genomics research centre, have recently launched Asia's first cloud platform that focuses on precision medicine and its applications.
The new cloud platform is expected to accelerate the advent of precision medicine in China, benefiting the medical, healthcare and wellness industries with new applications and research discoveries. This will enable the general public to enjoy more effective medical treatments and preventive healthcare services in the future.
Under this partnership, BGI will leverage its cloud-based BGI Online genome analytics engine to create a genomics data centre and analytics platform that will boost the precision medicine industry.
On the other hand, AliCloud will provide a cloud computing environment, big data analytics, and a supporting ecosystem; while Alibaba Group affiliates - such as Alibaba Health, Ant Financial Services Group, Taobao Marketplace and Tmall.com - will be responsible for services such as payment infrastructure, health management, and marketing support.
Lastly, Intel will contribute computing support optimised for genetic research to enable the processing and analysis of genetic data in a secure, private environment.
Access to the precision medicine platform is open to all stakeholders and supporters of China's precision medicine industry. The flexibility of its cloud infrastructure has enabled the new medical platform not only to satisfy stringent conditions for medical research, but also for the storage and transmission of sensitive genetic data. The advanced technologies comply with HIPAA stipulations and other industry requirements, enabling doctors and researchers to share information in a highly secure environment.
"With AliCloud's support, our BGI Online has become the basis of an open, collaborative cloud environment that is a win for all parties. The new platform will attract more users and developers to BGI's solutions, drive continued innovation for medicine, and grow a strong precision medicine industry," said YE Yin, CEO, BGI Ltd.
"The creation of this converged precision healthcare platform with BGI and AliCloud is a rare opportunity for Intel not only to work with in-country experts but also to use IT to accelerate our understanding of gene sequencing and analytics. The end goal is to empower researchers and doctors to help patients receive a diagnosis based on their genome and potentially arm clinicians with the data needed for a targeted treatment plan. By 2020, we envision this happening in 24 hours - All in One Day," added Intel Fellow Eric Dishman, who is also general manager, Health & Life Sciences at Intel.
Commenting further on this partnership, AliCloud President, Xiaoming Hu said, "We believe that BGI, AliCloud, and Intel are a powerful combination that will revolutionize gene sequencing technology. We will generate a number of positive outcomes for health, work together to publicize the power of computing, and bring incalculable value to society."
Sign up for CIO Asia eNewsletters.